CN113423702A - N-(吡啶-2-基)吡啶-磺酰胺衍生物及其在治疗疾病中的用途 - Google Patents

N-(吡啶-2-基)吡啶-磺酰胺衍生物及其在治疗疾病中的用途 Download PDF

Info

Publication number
CN113423702A
CN113423702A CN202080011826.1A CN202080011826A CN113423702A CN 113423702 A CN113423702 A CN 113423702A CN 202080011826 A CN202080011826 A CN 202080011826A CN 113423702 A CN113423702 A CN 113423702A
Authority
CN
China
Prior art keywords
pyridin
trifluoromethyl
sulfamoyl
amino
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080011826.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·阿奇米奥拉
陈蓓
R·埃普勒
J·P·拉伊内斯
C·J·N·马蒂松
J·纳巴卡
V·I·尼库林
S·帕特尔
D·P·菲利普斯
P·V·鲁克尔
A·瓦利尔
吴报根
晏珊珊
朱雪峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN113423702A publication Critical patent/CN113423702A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080011826.1A 2019-02-06 2020-02-04 N-(吡啶-2-基)吡啶-磺酰胺衍生物及其在治疗疾病中的用途 Pending CN113423702A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962801717P 2019-02-06 2019-02-06
US62/801,717 2019-02-06
PCT/IB2020/050884 WO2020161623A1 (en) 2019-02-06 2020-02-04 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease

Publications (1)

Publication Number Publication Date
CN113423702A true CN113423702A (zh) 2021-09-21

Family

ID=69528901

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080011826.1A Pending CN113423702A (zh) 2019-02-06 2020-02-04 N-(吡啶-2-基)吡啶-磺酰胺衍生物及其在治疗疾病中的用途

Country Status (5)

Country Link
US (1) US20220127247A1 (https=)
EP (1) EP3921313A1 (https=)
JP (1) JP2022519301A (https=)
CN (1) CN113423702A (https=)
WO (1) WO2020161623A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7214743B2 (ja) 2018-02-15 2023-01-30 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法
UY38630A (es) 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2021030552A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
IL300413A (en) 2020-08-13 2023-04-01 Vertex Pharma Crystal forms of CFTR modulators
KR20230118123A (ko) 2020-12-10 2023-08-10 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 치료 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189613A1 (en) * 2003-06-05 2006-08-24 David Cheshire Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4)
US20160355480A1 (en) * 2015-06-02 2016-12-08 Abbvie S.Á.R.L. Substituted pyridines and method of use
US20170001991A1 (en) * 2014-03-13 2017-01-05 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2018042316A1 (en) * 2016-08-29 2018-03-08 Novartis Ag N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189613A1 (en) * 2003-06-05 2006-08-24 David Cheshire Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4)
US20170001991A1 (en) * 2014-03-13 2017-01-05 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
US20160355480A1 (en) * 2015-06-02 2016-12-08 Abbvie S.Á.R.L. Substituted pyridines and method of use
WO2018042316A1 (en) * 2016-08-29 2018-03-08 Novartis Ag N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease

Also Published As

Publication number Publication date
EP3921313A1 (en) 2021-12-15
US20220127247A1 (en) 2022-04-28
JP2022519301A (ja) 2022-03-22
WO2020161623A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
TWI874398B (zh) Nlrp3炎性小體抑制劑
CN113423702A (zh) N-(吡啶-2-基)吡啶-磺酰胺衍生物及其在治疗疾病中的用途
AU2019404934B2 (en) Macrocyclic compounds and their use in the treatment of disease
EP3504194B1 (en) N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
CN103781763B (zh) 作为钾通道阻断剂的胺衍生物
CN116583502A (zh) 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途
AU2015266453B2 (en) Alk kinase inhibitor, and preparation method and use thereof
CN114981243A (zh) 用于治疗由cftr活性缺陷介导的疾病和病状的6元杂芳基氨基磺酰胺
TWI695831B (zh) Ｃｒｔｈ２拮抗劑化合物及其用途
TWI696625B (zh) ６,７-二氫吡唑並［１,５-α］吡-４（５Ｈ）-酮化合物及其作為ＭＧＬＵＲ２受體的負性別構調節物之用途
CN113226464A (zh) N-(吡啶-2-基磺酰基)环丙烷甲酰胺衍生物及其在治疗cftr介导的疾病中的用途
JPWO2020128925A5 (https=)
CN115043836A (zh) 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
CN107759620B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途
JP5739426B2 (ja) 置換ピリジン化合物
RU2804139C2 (ru) Макроциклические соединения и их применение в лечении заболевания
HK40126954A (zh) 募集cereblon的bcl-xl/bcl-2双重降解剂
TW202539638A (zh) 羧酸酯類化合物及其製備方法和用途
CN114341137A (zh) 二氢嘧啶衍生物及其用途
HK40063935A (zh) 多环tlr7/8拮抗剂及其在治疗免疫失调中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210921

WD01 Invention patent application deemed withdrawn after publication